Gapping down
In reaction to disappointing earnings/guidance: DG -2.8% (also files for 25 mln share common stock offering by selling shareholders).
M&A news: CTV -1.0% (announces end of "Go-Shop" Period; did not receive any alternative acquisition proposals).
Select financial related names showing weakness: BBVA -4.7%, STD -4.2%, ING -3.6%, CS -3.3%, DB -3.1%, UBS -3.0%, IBN -2.9%, BCS -2.8%, GFA -2.0%, RBS -1.6%, HBC -0.9%.
Select aluminum/steel related stocks trading lower: NUE -1.5%, AKS -1.1%, X -0.6%.
Select oil/gas related names showing weakness: RDS.A -1.5%, SDRL -1.4%, E -1.4%, TOT -1.3%.
Select telecom related names under pressure: TEF -2.9%, FTE -2.7%,
Other news: CELM -7.8% (files $50 mixed securities shelf offering), HGSI -4.7% and GSK -1.8% (Human Genome Sciences and GlaxoSmithKline Announce FDA Extension of BENLYSTA PDUFA Target Date to March 10, 2011), BBW -2.0% (modestly pulling back after surging into the close with Bloomberg reporting co is seeking buyer).
Analyst comments: CISG -3.5% (downgraded to Neutral from Overweight at JPMorgan), NVLS -1.9% (downgraded to Hold from Buy at Stifel Nicolaus; tgt $32 - based on valuation ), SNDK -1.3% (downgraded to Hold from Buy at ThinkEquity).
Gapping up
In reaction to strong guidance: MET 0.8%.
M&A news: VRGY +32.9% (Verigy receives unsolicited proposal from Advantest), BKS +17.8% (Pershing Square prepared to finance BGP offer to purchase BKS for $16/share - amended 13D filing), RDWR +14.4% (Hearing strength attributed to foreign newspaper article out over the weekend suggesting RVBD takeover).
Select metals/mining stocks trading higher: SHZ +3.3%, GRS +2.7%, EXK +2.5%, HL +2.1%, SLW +1.5%, PAL +1.3%, AUY +1.0%.
Other news: CBRX +15.2% (Watson Pharm and Columbia Lab announce positive top-line results from the PREGNANT Study), CBPO +5.4% (Special Committee completed its investigation of several allegations that appeared on certain financial websites), NVMI +4.7% (confirms another "top tier foundry" adopts Nova's Integrated Metrology Solution), GERN +3.8% (announced the presentation of final data from its Phase 2 clinical trial of GRNVAC1 at ASH), CYCC +3.3% (reports phase 2 survival data with Sapacitabine in Myelodysplastic Syndromes), AGN +3.2% (FDA Advisory Committee recommends approval to expand use of LAP-BAND adjustable gastric banding system for obese adults), MEE +2.0% (announced Don Blankenship will retire effective December 31, 2010; Baxter Phillips will succeed Blankenship as CEO), RNN +1.9% (announces U.S. Patent issued for new method for treating cognitive disorders), FNSR +1.5% (requests withdrawal of the Co's Registration Statement), UNG +1.0% (still checking), GOOG +0.9% (reports out over the weekend that GOOG and Groupon talks have ended).
Analyst comments: AEO +2.7% (upgraded to Buy from Neutral at Goldman), ELN +2.5% (upgraded to Buy from Neutral at UBS), CTSH +1.7% (upgraded to Buy from Neutral at Goldman), ANF +1.1% (added to Conviction Buy List at Goldman), CSCO +0.9% (upgraded to Outperform at Oppenheimer), TXN +0.5% (upgraded to Buy from Neutral at Sterne Agee).